Showing papers in "The Breast in 2015"

TL;DR: Data suggests that intrinsic molecular profiling provides clinically relevant information beyond current pathology-based classifications within triple-negative breast cancer (TNBC) and within hormone receptor-positive and HER2-negative early breast cancer.

TL;DR: How radiation dose levels in digital breast tomosynthesis (DBT) differ from those used in 2-view full-field digital mammography (FFDM) is examined, with substantial implications for population screening programs.

TL;DR: It is important to examine the prevalence, frequency and short/long-term impact of therapy-related toxicities, identify patients who might be at greatest risk and strive against the notion of recommending adjuvant systemic chemotherapy "just in case."

TL;DR: It is evident from the results of several ring trials that intermediate levels of Ki67 are particularly difficult for standardization and the clinical utility of intermediate Ki67 levels is limited, which supports the view that Ki67 is continuous marker, reflecting the continuous variation of the proliferation rate in different tumors.

TL;DR: It appears unlikely that mastectomy provides better OS compared to BCS + WBRT in early breast cancer patients aged 40 years or younger, from the present meta-analysis carried out on 22598 patients.

TL;DR: The findings indicate that clinical and imaging findings of Granulomatous Mastitis have overlapped with malignancy and the best diagnostic method is core needle biopsy.

TL;DR: The International-Breast-Cancer-Study- group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breasts-C cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy.

TL;DR: The molecular heterogeneity of TNBC is reviewed and the impact on previous and future clinical trials is reviewed.

TL;DR: Biopsies of recurrent lesions are needed to assess the changes in epi/genomics and signaling landscape of ER and associated pathways in order to tailor therapies to effectively overcome endocrine resistance.

TL;DR: Molecular mechanisms underlying resistance to HER2-targeted therapies are considered and evidence for strategies to manage resistance is evaluated, including the use of inhibitors of the PI3K/Akt/mTOR pathway.

TL;DR: The results regarding E-DII are consistent with previous studies reporting a lack of association between C-reactive protein, a marker of systemic inflammation, and postmenopausal breast cancer risk, and the findings may reflect a real absence of relationship between dietary inflammatory potential and post menopausal cancer risk or an underestimation of association due to recall bias.

TL;DR: Identifying the factors most often described in association with aggressive metastatic breast cancer and understanding their contribution to the aggressiveness of MBC and disease progression may lead to more personalized treatment in this patient population.

TL;DR: The literature provides a favourable view of 3D-SI, however, evidence of its superiority over current methods of clinical decision making, surgical planning, communication and evaluation of outcome is required before it can be accepted into mainstream practice.

TL;DR: NSM after NCH is not associated with a statistically significant difference in terms of post-operative complications, total nipple loss for necrosis or margins, and results improve with experience.

TL;DR: Fulfillment of the certification requirements was high and remained relatively stable over time, with the extent of variation between sites declining.

TL;DR: Postmenopausal women with hormone receptor positive, stage I-IIIA breast cancer, who had completed surgery, chemotherapy, and radiation, and were taking endocrine therapy are explored to explore how symptoms and psychosocial factors are related to intentional and unintentional non-adherent medication taking behaviors.

TL;DR: Adoption of some of the strategies identified in this article may lead to further improvements in outcomes for patients with the disease and improve the currently inadequate classification of breast cancer subtypes.

TL;DR: The three clinician-assessed scoring criteria (especially the RTOG and CTCAE criteria) show strong correlation with cutaneous blood flow measurements, but correlate less well with other skin biophysical parameters and patient-reported symptoms.

TL;DR: Women were positive about adjusting the frequency of mammography screening in line with personal genetic risk, but it will be important to develop effective communication materials to minimise resistance to reducing screening frequency for those at lower genetic risk.

TL;DR: Elevated preoperative plasma fibrinogen was independently associated with poor prognosis in breast cancer patients and may serve as a valuable parameter for risk assessment in Breast cancer patients.

TL;DR: Neoadjuvant treatment should be considered for all patients with HER2-positive or triple negative breast cancer, and clinical trials in this setting are currently investigating new approaches.

TL;DR: The potential use of circulating miRNAs to detect metastasis in discussed and the current barriers to their progression to the clinic are discussed.

TL;DR: In this paper, a prospective cohort study with 506 patients recruited at the Portuguese Institute of Oncology of Porto, among those newly diagnosed, was performed to quantify the incidence of neurological complications secondary to breast cancer treatment during the first year after diagnosis.

TL;DR: There was no apparent prolongation of estimated progression-free survival with the addition of trebananib to paclitaxel and bevacizumab at the doses tested, and exposure-response analyses support evaluation of combinations incorporating trebanAnib at doses > 10 mg/kg in this setting.

TL;DR: Whether or not the potentially higher radiosensitivity of normal and tumour cells has a clinical relevance in BRCA1/2 mutations carriers in terms of disease control, acute and late adverse events, and tumoursigenesis is determined.

TL;DR: The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia) and women with osteoporosis and those that consumed alcohol were also more likely to accept medication.

TL;DR: Striking similarities found between OBCS and mastectomy patients' histopathological results are in sharp contrast with previously published data, which suggests that oncological outcomes following OBCs should be compared to mastectomy besides WLE.

TL;DR: HT and RT are effective for locally advanced or recurrent breast cancer in patients that have been historically difficult to treat by RT alone and over 50% of patients achieved control of locoregional disease.

TL;DR: Improving diagnostic consistency, breast cancer risk prediction and education of physicians and patients regarding therapeutic prevention in women with benign breast disease may strengthen breast cancer prevention efforts.

TL;DR: Recent studies supplement the growing evidence that treatment of patients with MF/MC breast cancer with BCS, radiotherapy, and adjuvant systemic therapy can result in low rates of in-breast recurrence.